Systemic VHL gene functions and the VHL disease

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• The von Hippel-Lindau (VHL) gene functions as an E3 ubiquitin ligase, primarily known for negatively regulating the hypoxia-inducible factor (HIF).
• Mutations in VHL are implicated in various human diseases, including familial VHL tumor syndrome, sporadic renal cell carcinoma, and polycythemia.
• While VHL mutations can cause cell-autonomous effects within tumor cells, non-tumor cell-autonomous functions have also been observed.

Purpose of the Study:

• To explore the broader systemic functions of the VHL gene beyond its role in tumor cells.
• To understand how VHL loss-of-function impacts various cell types and contributes to VHL disease pathogenesis.
• To investigate the non-tumor cell-autonomous roles of VHL in disease development.

Main Methods:

• Analysis of VHL gene function and its interaction with HIF.
• Examination of VHL mutations and their effects on cellular phenotypes.
• Investigation of VHL tumor-derived factors and their systemic influence.

Main Results:

• VHL mutations lead to the up-regulation of HIF, affecting hematopoietic stem cells, endothelial cells, and myeloid cells.
• VHL tumor cells release cytokines that can promote inflammation and mobilize endothelial progenitor cells.
• Loss of VHL function contributes to both cell-autonomous and non-cell-autonomous phenotypes.

Conclusions:

• Systemic functions of VHL are crucial in the development of VHL disease.
• VHL's role extends beyond tumor suppression, influencing multiple cell types and systemic processes.
• Understanding VHL's non-cell-autonomous functions is key to comprehending VHL disease.